Antipsychotic and use thereof

Abstract

An object of the present invention is to provide a novel therapeutic agent for a mental disorder with abnormal neurodevelopment as a pathological condition. The present invention provides an antipsychotic drug containing a Rho kinase inhibitor as an active ingredient. The antipsychotic drug can be used, for example, in the treatment of schizophrenia, autism spectrum disorder, bipolar disorder, or depression.

1 . An antipsychotic drug comprising a Rho kinase inhibitor or a pharmacologically acceptable salt thereof as an active ingredient. 
     
     
         2 . The antipsychotic drug according to  claim 1 , which normalizes dysfunction of ARHGAP10. 
     
     
         3 . The antipsychotic drug according to  claim 1 , wherein the Rho kinase inhibitor is fasudil or ripasudil. 
     
     
         4 . The antipsychotic drug according to  claim 1 , which is for use in the treatment of a mental disorder with abnormal neurodevelopment as a pathological condition. 
     
     
         5 . The antipsychotic drug according to  claim 4 , wherein the mental disorder is caused by dysfunction of ARHGAP10. 
     
     
         6 . The antipsychotic drug according to  claim 4 , wherein the mental disorder is schizophrenia, autism spectrum disorder, bipolar disorder, or depression. 
     
     
         7 . A method for treating a mental disorder with abnormal neurodevelopment as a pathological condition, the method comprising the step of administering a therapeutically effective amount of a Rho-kinase inhibitor to a patient in need of treatment or prevention. 
     
     
         8 . The method according to  claim 7 , wherein the mental disorder is caused by dysfunction of ARHGAP10. 
     
     
         9 . The method according to  claim 7 , wherein the mental disorder is schizophrenia, autism spectrum disorder, bipolar disorder, or depression. 
     
     
         10 . The antipsychotic drug according to  claim 2 , wherein the Rho kinase inhibitor is fasudil or ripasudil. 
     
     
         11 . The method according to  claim 8 , wherein the mental disorder is schizophrenia, autism spectrum disorder, bipolar disorder, or depression.